The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics

European Journal of Clinical Pharmacology
L A JaberI R Welshman

Abstract

We have studied the pharmacokinetics and pharmacodynamics of glyburide during long-term therapy in 20 patients with type II diabetes mellitus. The patients were divided according to body mass index (BMI) into an obese group [n = 12, age 55(13) y, BMI 36.2(9.2) kg.m-2, total body weight (TBW) 100(23) kg], and a non-obese group [n = 8, age 61(13) y, BMI 24.5(2.1) kg.m-2, TBW 73(7) kg]. The dosages of glyburide were titrated to achieve specified therapeutic goals based upon serum glucose concentrations or to a maximum dosage of 20 mg per day. The pharmacokinetics of glyburide were determined at week 12 of treatment. On the study day, the patients took a 2.5 mg liquid test dose of glyburide with a Sustacal meal challenge. The elimination rate constant (lambda z), clearance (CL), and apparent volume of distribution (Vz) were 0.08 h-1, 3.3 l.h-1, and 47.0 l in the obese group, and 0.07 h-1, 3.1 l.h-1, and 56.8 l in the non-obese group. These values were not statistically significantly different. However, there were differences between the groups when the volume and clearance were corrected by TBW or BMI but not by ideal body weight (IBW) or fat-free mass (FFM). Regression analysis between the pharmacokinetic variables and body weight...Continue Reading

Citations

Oct 1, 1995·Journal of Clinical Pharmacy and Therapeutics·T RydbergA Melander
Oct 6, 2000·Clinical Pharmacokinetics·G Cheymol
Mar 28, 2012·Clinical Pharmacokinetics·Margreke J E BrillCatherijne A J Knibbe
Feb 12, 2004·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J L C M DorneA G Renwick
Dec 16, 2011·Journal of Pharmaceutical Sciences·Zvetanka Zhivkova, Irini Doytchinova
Oct 2, 2008·The Mount Sinai Journal of Medicine, New York·Brian Markoff, Alison Amsterdam
Feb 11, 2015·The Canadian Journal of Cardiology·Sowndramalingam SankaralingamRaj S Padwal
Jul 17, 2004·British Journal of Clinical Pharmacology·Bruce Green, Stephen B Duffull

Related Concepts

Blood Glucose
C-Peptide
Diabetes Mellitus
Diabetes Mellitus, Non-Insulin-Dependent
Neogluconin
Insulin B Chain
Obesity
Body Mass Index Procedure

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.